Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study. In the near future, patients won’t have to waste time and be disappointed with months of ineffective therapy, scientists said. Currently $2.5 billion a year is wasted on therapy that doesn’t work.